Biliary gastritis: modern methods of diagnosis and therapy
DOI: 10.32364/2587-6821-2022-6-5-244-251
M.A. Livzan1, O.V. Gaus1, S.I. Mozgovoi1, L.I. Telyatnikova2
1Omsk State Medical University, Omsk, Russian Federation
2Clinical Diagnostic Center "Ultramed", Omsk, Russian Federation
According to the prevalence, chronic biliary gastritis is among the most common etiological variants of chronic gastritis along with Helicobacter pylori associated gastritis and NSAID gastropathy. This review has been prepared to systematize data on the causes, pathogenetic mechanisms and methods of the diagnosis and therapy of chronic biliary gastritis. The widespread prevalance of biliary gastritis in clinical practice with insufficient understanding of the pathogenesis, the lack of diagnostic standards and unified treatment methods make the coverage of this problem very relevant. The review also systematizes known information about risk factors and pathogenetic mechanisms of biliary gastritis, discusses methods of the diagnosis and treatment of this disease, in particular, the use of ursodeoxycholic acid and cytoprotectors as pathogenetic therapy. The authors note that the treatment of biliary gastritis should be comprehensive and aimed not only at relieving dyspeptic symptoms and improving the life quality of patients, but also at preventing and inhibiting atrophic changes in the gastric mucosa.
Keywords: biliary gastritis, duodenogastric reflux, reactive gastritis, bile reflux gastropathy, reactive gastropathy, ursodeoxycholic acid, cytoprotectors.
For citation: Livzan M.A., Gaus O.V., Mozgovoi S.I., Telyatnikova L.I. Biliary gastritis: modern methods of diagnosis and therapy. Russian Medical Inquiry. 2022;6(5):244–251 (in Russ.). DOI: 10.32364/2587-6821-2022-6-5-244-251.
About the authors:
Maria A. Livzan — Dr. Sc. (Med.), Professor, Corresponding Member of the RAS, Head of the Department of Faculty Therapy and Gastroenterology, Chancellor Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0002-6581-7017.
Olga V. Gaus — C. Sc. (Med.), Assistant Professor of the Department of Faculty Therapy and Gastroenterology, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0001-9370-4768.
Sergei I. Mozgovoy — Dr. Sc. (Med.), Associate Professor, Professor of the Department of Pathological Anatomy, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0002-6733-5572.
Larisa I. Telyatnikova — Head of the Department of Endoscopy, Clinical Diagnostic Center "Ultramed"; 12, Chkalov str., Omsk, 644024, Russian Federation; ORCID iD 0000-0003-0876-7217.
Contact information: Olga V. Gaus, e-mail: gaus_olga@bk.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 04.04.2022.
Revised 27.04.2022.
Accepted 26.05.2022.
2. Sugano K., Tack J., Kuipers E.J. et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367. DOI: 10.1136/gutjnl-2015-309252.
3. Chen L., Zhu G., She L. et al. Analysis of Risk Factors and Establishment of a Prediction Model for Endoscopic Primary Bile Reflux: A Single-Center Retrospective Study. Front Med (Lausanne). 2021;8:758771. DOI: 10.3389/fmed.2021.758771.
4. Keane F.B., Dimagno E.P., Malagelada J.R. Duodenogastric reflux in humans: its relationship to fasting antroduodenal motility and gastric, pancreatic, and biliary secretion. Gastroenterology. 1981;81(4):726–731. PMID: 7262517.
5. Li X.B., Lu H., Chen H.M. et al. Role of bile reflux and Helicobacter pylori infection on inflammation of gastric remnant after distal gastrectomy. J Dig Dis. 2008;9(4):208–212. DOI: 10.1111/j.1751-2980.2008.00348.x.
6. Aprea G., Canfora A., Ferronetti A. et al. Morpho-functional gastric pre-and post-operative changes in elderly patients undergoing laparoscopic cholecystectomy for gallstone related disease. BMC Surg. 2012;12 Suppl 1(Suppl 1):S5. DOI: 10.1186/1471-2482-12-S1-S5.
7. Pizza F., D’Antonio D., Lucido F.S. et al. Postoperative Clinical-Endoscopic Follow-up for GERD and Gastritis After One Anastomosis Gastric Bypass for Morbid Obesity: How, When, and Why. Obes Surg. 2020;30(11):4391–4400. DOI: 10.1007/s11695-020-04805-9.
8. Zobolas B., Sakorafas G.H., Kouroukli I. et al. Alkaline reflux gastritis: early and late results of surgery. World J Surg. 2006;30(6):1043–1049. DOI: 10.1007/s00268-005-0418-x.
9. McCabe M.E. 4th, Dilly C.K. New Causes for the Old Problem of Bile Reflux Gastritis. Clin Gastroenterol Hepatol. 2018;16(9):1389–1392. DOI: 10.1016/j.cgh.2018.02.034.
10. Lake A., Rao S.S.C., Larion S. et al. Bile Reflux Gastropathy and Functional Dyspepsia. J Neurogastroenterol Motil. 2021;27(3):400–407. DOI: 10.5056/jnm20102.
11. Liu H., Hu C., Zhang X., Jia W. Role of gut microbiota, bile acids and their cross-talk in the effects of bariatric surgery on obesity and type 2 diabetes. J Diabetes Investig. 2018;9(1):13–20. DOI: 10.1111/jdi.12687.
12. Stellaard F., Sackmann M., Sauerbruch T., Paumgartner G. Simultaneous determination of cholic acid and chenodeoxycholic acid pool sizes and fractional turnover rates in human serum using 13C-labeled bile acids. J Lipid Res. 1984;25(12):1313–1319. PMID: 6530587.
13. Akhmedov V.A., Gaus O.V. Modern views on development mechanisms and tactics for treatment ofpatients with gallbladder disease associated with metabolic syndrome. Medical alfafit. 2019;2(13):52–57 (in Russ.). DOI: 10.33667/2078-5631-2019-2-13(388)-52-56.
14. Zwartjes M.S.Z., Gerdes V.E.A., Nieuwdorp M. The Role of Gut Microbiota and Its Produced Metabolites in Obesity, Dyslipidemia, Adipocyte Dysfunction, and Its Interventions. Metabolites. 2021;11(8):531. DOI: 10.3390/metabo11080531.
15. Dawson P.A. Role of the intestinal bile acid transporters in bile acid and drug disposition. Handb Exp Pharmacol. 2011;(201):169–203. DOI: 10.1007/978-3-642-14541-4_4.
16. Bechi P., Amorosi A., Mazzanti R. et al. Reflux-related gastric mucosal injury is associated with increased mucosal histamine content in humans. Gastroenterology. 1993;104(4):1057–1063. DOI: 10.1016/0016-5085(93)90274-g.
17. Goldman A., Shahidullah M., Goldman D. et al. A novel mechanism of acid and bile acid-induced DNA damage involving Na+/H+ exchanger: implication for Barrett’s oesophagus. Gut. 2010;59(12):1606–1616. DOI: 10.1136/gut.2010.213686.
18. Choi J., Kim S.G., Yoon H. et al. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol. 2014;12(5):793–800.e1. DOI: 10.1016/j.cgh.2013.09.057.
19. Igarashi M., Nakae H., Matsuoka T. et al. Alteration in the gastric microbiota and its restoration by probiotics in patients with functional dyspepsia. BMJ Open Gastroenterol. 2017;4(1):e000144. DOI: 10.1136/bmjgast-2017-000144.
20. He Q., Liu L., Wei J. et al. Roles and action mechanisms of bile acid-induced gastric intestinal metaplasia: a review. Cell Death Discov. 2022;8(1):158. DOI: 10.1038/s41420-022-00962-1.
21. Straub D., Oude Elferink R.P.J., Jansen P.L.M. et al. Glyco-conjugated bile acids drive the initial metaplastic gland formation from multi-layered glands through crypt-fission in a murine model. PLoS One. 2019;14(7):e0220050. DOI: 10.1371/journal.pone.0220050.
22. Matsuhisa T., Tsukui T. Relation between reflux of bile acids into the stomach and gastric mucosal atrophy, intestinal metaplasia in biopsy specimens. J Clin Biochem Nutr. 2012;50(3):217–221. DOI: 10.3164/jcbn.11-90.
23. Matsuhisa T., Arakawa T., Watanabe T. et al. Relation between bile acid reflux into the stomach and the risk of atrophic gastritis and intestinal metaplasia: a multicenter study of 2283 cases. Dig Endosc. 2013;25(5):519–525. DOI: 10.1111/den.12030.
24. Takahashi Y., Uno K., Iijima K. et al. Acidic bile salts induces mucosal barrier dysfunction through let-7a reduction during gastric carcinogenesis after Helicobacter pylori eradication. Oncotarget. 2018;9(26):18069–18083. DOI: 10.18632/oncotarget.24725.
25. Livzan M.A., Kononov A.V., Mozgovoy S.I. Post-eradication period of chronic gastritis associated with Helicobacter pylori infection. Consilium medicum. 2008;10(8):15–20 (in Russ.).
26. Livzan M.A., Gaus O.V., Mozgovoi S.I. Chronic atrophic gastritis: patient management. Russian Medical Inquiry. 2021;5(6):427–432 (in Russ.). DOI: 10.32364/2587-6821-2021-5-6-427-432.
27. Li D., Zhang J., Yao W.Z. et al. The relationship between gastric cancer, its precancerous lesions and bile reflux: A retrospective study. J Dig Dis. 2020;21(4):222–229. doi: 10.1111/1751–2980.12858.
28. Osipenko M.F., Livzan M.A. Approaches to diagnostic and therapy of gastritis associated with bile reflux. Lechaschi vrach. 2012;2:50 (in Russ.).
29. Matysiak-Budnik T., Heyman M., Mégraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18 Suppl 1:55–62. doi: 10.1046/j.1365–2036.18.s1.6.x.
30. Naito Y., Yoshikawa T., Tanigawa T. et al. Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med. 1995;18(1):117–123. DOI: 10.1016/0891-5849(94)00110-6.
31. Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261–270. DOI: 10.1586/egh.10.25.
32. Maev I.V., Kazyulin A.N. New opportunities for the prevention of gastric cancer. Terapevticheskii arkhiv. 2017;89(4):101–109 (in Russ.). DOI: 10.17116/terarkh2017894101-109.
33. Hou D., Yang M., Hu Z., Yang L. Effects of rebamipide for chronic atrophic gastritis: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2020;99(25):e20620. DOI: 10.1097/MD.0000000000020620.
34. Han X., Jiang K., Wang B. et al. Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study. Clin Drug Investig. 2015;35(10):665–673. DOI: 10.1007/s40261-015-0329-z.
35. Kamada T., Sato M., Tokutomi T. et al. Rebamipide improves chronic inflammation in the lesser curvature of the corpus after Helicobacter pylori eradication: a multicenter study. Biomed Res Int. 2015;2015:865146. DOI: 10.1155/2015/865146.
36. Uno Y. Prevention of gastric cancer by Helicobacter pylori eradication: A review from Japan. Cancer Med. 2019;8(8):3992–4000. DOI: 10.1002/cam4.2277.
37. Stefaniwsky A.B., Tint G.S., Speck J. et al. Ursodeoxycholic acid treatment of bile reflux gastritis. Gastroenterology. 1985;89(5):1000–1004. DOI: 10.1016/0016-5085(85)90200.
38. Minushkin O.N., Zverkov I.V., Skibina Yu.S. Some approaches to treatment of patients with chronic (biliary) reflux gastritis. Medical alphabet. 2017;2(19):28–31 (in Russ.).
39. Ivashkin V.T., Mayev I.V., Lapina T.L. et al. Diagnostics and treatment of Helicobacter pylori infection in adults: clinical guidelines of the Russian gastroenterological association. Ross z gastroenterol gepatol koloproktol. 2018;28(1):55–70 (in. Russ.). DOI: 10.22416/1382-4376-2018-28-1-55-70.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать